Last reviewed · How we verify
Low Molecular Weight Iron Dextran
Low molecular weight iron dextran delivers iron directly into cells to replenish iron stores and treat iron deficiency anemia.
Low molecular weight iron dextran delivers iron directly into cells to replenish iron stores and treat iron deficiency anemia. Used for Iron deficiency anemia in patients who cannot tolerate or have failed oral iron therapy.
At a glance
| Generic name | Low Molecular Weight Iron Dextran |
|---|---|
| Also known as | INFeD, LMW-ID, Cosmofer |
| Sponsor | University of Washington |
| Drug class | Iron replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron dextran is a colloidal complex of ferric hydroxide and dextran that allows parenteral iron delivery. The low molecular weight formulation has improved pharmacokinetics and reduced immunogenicity compared to higher molecular weight versions, enabling more efficient cellular uptake of iron for hemoglobin synthesis and correction of iron deficiency states.
Approved indications
- Iron deficiency anemia in patients unable to tolerate or absorb oral iron
- Iron deficiency anemia in chronic kidney disease patients on hemodialysis
Common side effects
- Injection site reactions (pain, discoloration)
- Hypersensitivity reactions
- Headache
- Arthralgia
- Fever
Key clinical trials
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma (PHASE4)
- Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality (NA)
- Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia (PHASE4)
- Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women (PHASE2)
- Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Molecular Weight Iron Dextran CI brief — competitive landscape report
- Low Molecular Weight Iron Dextran updates RSS · CI watch RSS
- University of Washington portfolio CI